SanguiBioTech Yields Revenues of over USD31,000 in Q2 2015 According to Preliminary Figures

WITTEN, Germany--()--According to preliminary, unaudited figures Sangui Biotech International, Inc. yielded revenues from royalties and product sales of more than USD31,000 in the course of the second quarter of its financial year 2015, ended December 31, 2014. In the first quarter of the 2015 financial year (ended September 30, 2014) revenues had amounted to USD73,740; in the second quarter of its financial year 2014 (ended December 31, 2013) the company reported revenues of USD33,776. According to those preliminary figures, revenues in the first six months of the 2015 financial year amounted to approximately USD105,000 after USD60,303 in the respective period of the previous year.

Sangui Biotech International, Inc.,

Revenue Development for the 2013 through 2015

Financial Years (per quarter)

                   

Fin. Quarter

USD
2013 Q1 20,549
2013 Q2 27,494
2013 Q3 33,388
2013 Q4 24,056
2014 Q1 26,527
2014 Q2 33,776
2014 Q3 29,438
2014 Q4 43,729
2015 Q1 73,740
2015 Q2 (p) >31,000
 

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB marketplace (www.otcmarkets.com: SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges. Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Sangui Biotech
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing@sangui.de

Contacts

Sangui Biotech
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing@sangui.de